Free Trial

Seres Therapeutics (MCRB) Competitors

Seres Therapeutics logo
$14.07 -0.01 (-0.07%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$14.80 +0.73 (+5.22%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MCRB vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRA

Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry.

Seres Therapeutics vs. Its Competitors

Seres Therapeutics (NASDAQ:MCRB) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Seres Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Seres Therapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$126.32M0.97$140K-$4.60-3.06
aTyr PharmaN/AN/A-$64.02M-$0.81-7.40

In the previous week, aTyr Pharma had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for aTyr Pharma and 1 mentions for Seres Therapeutics. aTyr Pharma's average media sentiment score of 0.42 beat Seres Therapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
aTyr Pharma
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Seres Therapeutics presently has a consensus price target of $73.67, suggesting a potential upside of 423.57%. aTyr Pharma has a consensus price target of $20.20, suggesting a potential upside of 237.23%. Given Seres Therapeutics' higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
aTyr Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

aTyr Pharma's return on equity of -87.09% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -41,084.76% -55.87%
aTyr Pharma N/A -87.09%-64.77%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

aTyr Pharma beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCRB vs. The Competition

MetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$122.86M$2.93B$5.53B$9.41B
Dividend YieldN/A2.48%3.76%4.04%
P/E Ratio-3.0619.8828.2619.78
Price / Sales0.97293.75412.9994.60
Price / CashN/A41.8435.8558.18
Price / Book8.747.678.115.65
Net Income$140K-$55.28M$3.25B$257.97M
7 Day Performance11.93%4.87%1.63%3.74%
1 Month Performance90.14%13.14%7.62%11.95%
1 Year Performance-42.57%3.51%32.74%19.22%

Seres Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCRB
Seres Therapeutics
2.897 of 5 stars
$14.07
-0.1%
$73.67
+423.6%
-42.6%$122.86M$126.32M-3.06330News Coverage
Gap Up
ATYR
aTyr Pharma
2.2397 of 5 stars
$5.53
+4.3%
$20.20
+265.3%
+265.2%$492.17M$230K-6.8353News Coverage
Gap Up
High Trading Volume
SIGA
Siga Technologies
1.9894 of 5 stars
$6.86
+1.3%
N/A-29.2%$490.08M$138.72M10.2440
TRML
Tourmaline Bio
1.9813 of 5 stars
$18.96
+5.5%
$49.33
+160.2%
+25.6%$486.99MN/A-5.9144News Coverage
Positive News
CGEM
Cullinan Therapeutics
1.9285 of 5 stars
$7.87
+2.2%
$30.00
+281.2%
-58.8%$464.41MN/A-2.7030
MBX
MBX Biosciences
2.4153 of 5 stars
$13.87
+6.4%
$37.50
+170.4%
N/A$463.59MN/A0.0036News Coverage
Analyst Forecast
RZLT
Rezolute
2.4206 of 5 stars
$5.32
+1.1%
$11.83
+122.4%
+19.2%$454.97MN/A-4.6340News Coverage
KMDA
Kamada
3.8276 of 5 stars
$7.78
+0.4%
$13.00
+67.1%
+28.9%$447.39M$167.24M26.83360Positive News
TERN
Terns Pharmaceuticals
3.5921 of 5 stars
$5.11
+4.3%
$15.63
+205.8%
-33.5%$446.31MN/A-4.6940
RGNX
REGENXBIO
3.7745 of 5 stars
$8.70
+0.2%
$31.63
+263.5%
-35.1%$436.39M$83.33M-2.80370News Coverage
Analyst Revision
SVRA
Savara
2.1427 of 5 stars
$2.51
+5.0%
$5.60
+123.1%
-49.4%$433.83MN/A-5.2320News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:MCRB) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners